The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
2don MSN
Reducing inflammation may protect against early age-related macular degeneration-like vision loss
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
Phoenix is the new Silicon Valley.
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...
Strategic Update and New Path to Value CreationPalm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: ...
In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback